ASX Share rice
Thu 13 May 2021 - 02:00:pm (Sydney)

PAR Share Price

PARADIGM BIOPHARMACEUTICALS LIMITED..PARPharmaceuticals, Biotechnology & Life Sciences

PAR Company Information

Name:

Paradigm Biopharmaceuticals Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

500 Collins Street Melbourne VIC Australia 3000

Phone:

61 3 9629 5566

CEO, MD & Exec. Chairman:

Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC

Chief Financial Officer:

Mr. Justin Cahill

Chief Operating Officer:

Dr. Jeannette Joughin

Chief Scientific Officer:

Dr. Ravi Krishnan

Director of Investor Relations:

Ms. Simon White

Global Head of Safety:

Dr. Michael Imperiale

Chief Medical Officer & Exec. Director:

Dr. Donna L. Skerrett

Commercial Head:

Ms. Beverley Huttmann

Global Head of Regulatory Affairs:

Ms. Michelle Coffey

Company Sec.:

Mr. Kevin G. Hollingsworth

Company Overview:

Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

PAR Share Price Information

Shares Issued:

228.07M

Market Capitalisation:

$467.54M

Revenue (TTM):

$3.08M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.109

Operating Margin (TTM):

$-9.41

Return On Assets (TTM):

$-0.20

Return On Equity (TTM):

$-0.33

Quarterly Revenue Growth (YOY):

-0.692

Gross Profit(TTM):

$3.65M

Diluted Earnings Per Share (TTM):

$-0.128

PAR CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$5.75M

Change To Liabilities:

$751.03K

Total Cashflow From Investing Activities:

$5.62M

Net Borrowings:

$1.80M

Net Income:

$-12,298,887

Total Cash From Operating Activities:

$-10,090,057

Depreciation:

$213.12K

Other Cashflow From Investing Activities:

$5.75M

Change To Account Receivables:

$22.45K

Sale Purchase Of Stock:

$36.84M

Capital Expenditures:

$127.54K

PAR Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-12,298,890

Net Income:

$-12,298,890

Operating Income:

$-12,264,720

Other Operating Expenses:

$-142,358

Interest Expense:

$34.17K

Total Revenue:

$4.70M

PAR Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$2.95M

Total Liabilities:

$4.18M

Total Stockholder Equity:

$108.18M

Total Assets:

$112.36M

Common Stock:

$145.87M

Retained Earnings:

$-41,268,546

Other Liabilities:

$68.39K

Other Assets:

$102.62K

Cash:

$103.92M

Total Current Liabilities:

$3.36M

Property - Plant & Equipment:

$0.94M

Net Tangible Assets:

$105.23M

Long-Term Investments:

$102.62K

Total Current Assets:

$108.37M

Net Receivables:

$3.51M

Short-Term Investments:

$3.99M

Accounts Payable:

$2.75M

Short-Term Investments:

$3.99

Non Current Liabilities Total:

$817.35K

PAR Share Price History

PAR News

25 Apr, 2021
Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock...
24 Jan, 2021
With the business potentially at an important milestone, we thought we'd take a closer look at Paradigm...
10 Dec, 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
27 Oct, 2020
In this article we are going to estimate the intrinsic value of Paradigm Biopharmaceuticals Limited (ASX:PAR) by...
11 Sep, 2020
It might be of some concern to shareholders to see the Paradigm Biopharmaceuticals Limited (ASX:PAR) share price down...